Drug Search Results
More Filters [+]

Polmacoxib

Alternative Names: polmacoxib, cg100649, cgl-1802, cgl1802, cgl 1802, cg-1801, cg1801, cg 1801
Latest Update: 2024-07-02
Latest Update Note: News Article

Product Description

Mechanisms of Action: COX2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Korea | Lebanon | Russia

Approved Indications: None

Known Adverse Events: None

Company: CrystalGenomics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Polmacoxib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Osteoarthritis, Knee|Osteoarthritis, Hip

Phase 2: Osteoarthritis, Hip|Osteoarthritis, Knee|Osteoarthritis

Phase 1: Hypertension|Healthy Volunteers|Osteoarthritis|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CG100651-1-01

P1

Completed

Healthy Volunteers

2020-04-30

27%

CG100649-1-07

P1

Completed

Healthy Volunteers

2019-05-03

28%

CG100650-1-01

P1

Completed

Healthy Volunteers

2019-04-04

27%

CG100649-3-01

P3

Completed

Osteoarthritis, Hip|Osteoarthritis, Knee

2013-12-01

Recent News Events